Learning Objectives

Thursday, April 11                           

Balancing Therapies in Patients with Hyperkalemia and Heart Failure

Speaker TBD

  1. Identify the causes and consequences of hyperkalemia for patients with heart failure.
  2. List the normal range of blood potassium, and the levels measured that would indicate a patient that is hypokalemic or hyperkalemic.
  3. Describe best practice recommendations regarding the use of RAAS inhibitors and potassium binders in the management of patients with comorbid conditions including heart failure, CVD and chronic kidney disease.
  4. Using case studies, describe the role of shared decision-making in the current treatment options for hyperkalemia.

Aspirin: The Magic Bullet for Prevention of CVD and Cancer?

Yin Cao, MPH, ScD, Kathy Berra MSN, ANP-BC

  1. List the benefits and harms of using aspirin to prevent CVD and cancer.
  2. Summarize the evidence-based recommendations for prescribing aspirin in primary and secondary prevention of CVD.
  3. Describe available aspirin preparations and their clinical application in patients with CVD and other co-morbid conditions.

An Integrative Approach to Managing Pain in an Era of Opioid Misuse and Addiction

Randall Hudspeth, PhD, MBA, MS, APRN-CNP/CNS, FRE, FAANP, NEA-BC

  1. Review the current crisis as it relates to opioid misuse and addiction.
  2. Define opioid use disorder and describe how it is diagnosed.
  3. List risk factors for “chemical coping”, available screening tools and strategies to identify patients at higher risk for nonmedical opioid use.
  4. Describe best practices, including pharmacologic and non-pharmacologic therapies, for managing acute and chronic pain in patients with cardiovascular disease

Building Strong Bones: What CV Nurses Need to Know about Fracture Prevention and Osteoporosis

Nancy Berman MSN, ANP-BC, NCMP, FAANP

  1. Describe risk factors for bone fracture and the use of bone densitometry and the FRAX calculation to determine 10-year risk.
  2. List strategies for the prevention of low bone density and fracture.
  3. Discuss evidence-based pharmacologic therapy for the management of osteopenia and osteoporosis including long-term use of drugs and drug holidays.
  4. Apply shared decision-making strategies (risk vs benefit analysis) within clinical cases to optimize treatment plans incorporating current evidence in the management of bone health.

Asthma, COPD and CVD: Why is everyone short of breath?

Lori Wilken, PharmD

  1. Define and describe classification systems for asthma and COPD and the related implications for pharmacological treatment and patient management.
  2. Discuss medications prescribed in the management of asthma and COPD including short and long-acting bronchodilators, corticosteroids, leukotriene modifiers, and theophylline, highlighting the clinical considerations in patients with CVD and interactions with medications commonly used to treat CVD.

Exercise and Lifestyle Interventions: What’s their Role in CVD Prevention and Treatment?

Geoffrey Moore MD & Kim Newlin RN, MS, ANP

  1. Discuss the benefits of incorporating exercise, physical activity and other lifestyle interventions in CVD prevention and treatment plans.
  2. Identify the dose of physical activity and level of cardiorespiratory fitness associated with positive CVD-health outcomes including the management of cardiometabolic risk factors.
  3. Describe the nurse’s role in exercise prescription and lifestyle counseling and list common barriers and facilitators to adoption of healthy behaviors.

Lipid Management in 2019: Putting Evidence-Based Guidelines into Practice

Lynne Braun RN ANP PhD

  1. Review current evidence-based guidelines for the management of dyslipidemia.
  2. Outline non-pharmacologic strategies for management of elevated LDL-C and triglycerides.
  3. Identify guideline-based pharmacotherapy for the management of dyslipidemia and use case examples to discuss their clinical application.

Case Studies in Cardiovascular Risk Reduction with Non-statin Therapies: Rapid Fire Roundtable

Speakers: TBD

  1. Review the latest clinical evidence regarding the impact of PCSK9 inhibitors and very low LDL-C on CV outcomes.
  2. Utilize PCSK9 inhibitors in patients who may benefit in accordance with the latest clinical evidence and recommendations.

Friday, April 12

Treating High-Risk Patients with Non-Statin Therapy for LDL-C Lowering: Optimizing Clinical Outcomes

Susan Halli-Demeter DNP, FNP-BC, CLS, FPCNA, FNLA & Karol Watson MD, PhD, FACC

  1. Discuss the benefits of incorporating exercise, physical activity and other lifestyle interventions in CVD prevention and treatment plans.
  2. Identify the dose of physical activity and level of cardiorespiratory fitness associated with positive CVD-health outcomes including the management of cardiometabolic risk factors.
  3. Describe nurses’ role in exercise prescription and lifestyle counseling and list common barriers and facilitators to adoption of healthy behaviors.

Women and CVD: Creating Awareness and Making Prevention a Priority

Sharonne Hayes, MD

  1. Identify key strategies to increase awareness of heart disease in women and review the role that WomenHeart has played in raising awareness and empowering women heart patients to champion this effort.
  2. Describe how heart disease manifests in women, when compared to men, including the role of microvascular dysfunction.
  3. Review strategies for cardiovascular risk management in women and their individual and additive impact of CVD prevention.

Cardio-Oncology: Preventing and Treating Cardiovascular Complications Associated with Cancer Treatments

Tochi Okwuosa, MD

  1. Define the common types of cancer treatments that may damage the heart and blood vessels.
  2. Describe CVD risk factors in cancer survivors and how to prevent and manage them.

The QT Interval: Too Hot, Too Cold, Just Right

Mike Ackerman, MD

  1. Review the pathophysiology of common causes of cardiac syncope including long QT syndrome.
  2. Briefly describe steps in evaluation and management of cardiac syncope with a focus on counseling patients to return to work and sport.

Concurrent Session: Is it Cardiac or Pulmonary? Patient Assessment and Diagnostic Evaluation of Dyspnea

Susan Corbridge, PhD, APRN

  1. Define and describe dyspnea and its most common underlying pathophysiologic causes.
  2. Review steps in a patient assessment for acute and chronic dyspnea including typical diagnostic and laboratory tests.

Concurrent Session: Multi-Cultural Health and CVD: Risk Assessment and Management in Ethnic Populations

May Hang, RN, MS, NP

  1. Describe the health disparities and variation in CVD risk profiles within racial and ethnic groups.
  2. Review the role of acculturation and health behaviors among ethnic populations.
  3. List three or more strategies to help CV nurses deliver culturally competent care to varied racial and ethnic groups.

Saturday, April 13

Making the Link Between Diabetes and Cardiovascular Disease

Marilyn Tan, MD & Cindy Lamendola, MSN, NP

  1. Describe how to integrate current guideline recommendations for diabetes therapies into clinical practice.
  2. Identify co-morbid conditions that impact choice of therapy. Summarize clinical trial data supporting the use of antidiabetic therapy in reducing cardiovascular risks and improving outcomes.
  3. Explain a multidisciplinary, team-based approach to management of the patient with Type 2 Diabetes highlighting the role of the CV clinician.

Lower Extremity PAD: How to Help Your Patients Get Back on their Feet

Diane Treat-Jacobsen, RN, PhD

  1. Highlight the signs, symptoms and risk factors of lower extremity PAD and its relationship with CVD.
  2. Review common steps in the assessment and evaluation of a patient with leg pain due to claudication.
  3. Outline non-pharmacologic and pharmacologic strategies for the management of PAD including the benefits of supervised exercise training.

Regenerative Medicine, Stem Cells and Heart Disease: Current Applications and Future Directions

Tim Nelson, MD

  1. Describe the role of regenerative medicine in repairing irreversibly damaged heart tissue and advanced heart failure.
  2. Discuss research and clinical trials underway to develop new therapies to cure ischemic heart disease, reduce myocardial injury, protect the heart against inflammation and form new blood vessels.

Advancing Patient Centered Care Through Shared Decision Making

Victor Montori, MD

  1. Define shared decision making as a process and its contribution to providing patient centered care.
  2. List examples of shared decision-making tools and how they are used in clinical practice with a focus on cardiovascular disease prevention and treatment.

Join us at the 25th Cardiovascular Nursing Symposium

Attend the live meeting or join us via the webcast.